In patients with moderate Alzheimer's disease, an experimental drug that alters the brain's "fight or flight" impulse succeeded in improving memory modestly when it was added to at least one of the medications already in wide use to treat the memory-robbing disease.
Compared with subjects taking the drug memantine and a placebo, subjects supplementing their customary drug regimen for three months with the experimental drug--ORM-12741--scored more highly on two measures of memory. One of those tested the quality of patients' memory overall; the other tested the quality of patients' "episodic memory"--the ability to recall events and experiences from one's own past.
In subjects taking the lower of the two doses tested, researchers at Finnish drug developer Orion Pharmaceuticals found a slight improvement in working memory--the ability to hold several items in memory for a minute or two. But the benefits were too small to be reliably attributed to the drug.
During the 12-week study period, the performance of subjects on memantine-plus-placebo on memory tests declined on average 33%. Those who took memantine-plus-ORM-12741 improved their scores on overall memory function by 4%.